brain metastasesALK+ NSCLCALK-positive NSCLCcrizotinibbrigatinibtyrosine kinase inhibitor (TKI) therapyTKI therapy
…red to using only baseline features in ALK+ NSCLC patients with brain metastases receiving TKI therapy. These findings highlight the potential o…